Eff orts are underway for early-phase trials of candidate treatments for cerebral amyloid angiopathy, an untreatable cause of haemorrhagic stroke and vascular cognitive impairment. A major barrier to these trials is the absence of consensus on measurement of treatment eff ectiveness. A range of potential outcome markers for cerebral amyloid angiopathy can be measured against the ideal criteria of being clinically meaningful, closely representative of biological progression, effi cient for small or short trials, reliably measurable, and cost eff ective. In practice, outcomes tend either to have high clinical salience but low statistical effi ciency, and thus more applicability for late-phase studies, or greater statistical effi ciency but more limited clinical meaning. The most statistically effi cient markers might be those that are potentially reversible with treatment, although their clinical signifi cance remains unproven. Many of the candidate outcomes for cerebral amyloid angiopathy trials are probably applicable also to other small-vessel brain diseases.
Introduction
Cerebrovascular deposition of amyloid (cerebral amyloid angiopathy) is a major cause of spontaneous intracerebral haemorrhage in elderly people and an important contributor to age-related cognitive decline. 1 Cerebral amyloid angiopathy is increasingly diagnosed during life by detection of vascular amyloid in pathological samples or detection of lobar haemorrhagic lesions by neuroimaging according to the validated Boston criteria. 2 There are many plausible approaches to prevention or treatment of cerebral amyloid angiopathy (eg, inhibition of β-amyloid peptide production, enhancement of β-amyloid clearance, or protection of vessels from the toxic eff ects of β-amyloid), and a phase 2 monoclonal antibody study (NCT01821118) has been recently initiated, but as yet there are no largescale clinical trials.
A barrier to cerebral amyloid angiopathy trials is the absence of consensus regarding outcome markers for measurement of treatment eff ectiveness. An ideal cerebral amyloid angiopathy marker would be one that is clinically meaningful, closely representative of the disease's underlying biological progression, effi cient at detecting changes in response to treatment, reliably and reproducibly measurable, and easily generalisable across many trial sites. In practice, no one marker will have all these desired features, resulting in trade-off s between effi cient surrogate markers useful for early-phase studies aimed at identifi cation of promising candidate treatments and clinically meaningful markers for pivotal studies to establish those treatments for medical use.
In this Review, which emerged from proceedings of the International Cerebral Amyloid Angiopathy Conference, Leiden, Netherlands, Oct 24-26, 2012, we discuss potential markers for clinical cerebral amyloid angiopathy trials on the basis of present understanding of the underlying biology and neurological eff ect of the disease. Emerging data suggest that advanced cerebral amyloid angiopathy can be measured by a wide range of markers, including clinical events (eg, symptomatic intracerebral haemorrhage or cognitive decline), structural brain lesions (eg, microbleeds, white matter hyperintensities, or microinfarcts), alterations of vascular physiology, and direct visualisation with amyloid radioligands. Each marker comes with particular drawbacks, such as the non-specifi city of structural brain lesions for cerebral amyloid angiopathy (vs other small-vessel diseases) or of amyloid radioligands for vascular β-amyloid (vs senile plaques). Nonetheless, rapidly accumulating data on invivo detection of the pathogenic steps involved in cerebral amyloid angiopathy off ers substantial promise for future trials aimed at identifying disease-modifying treatments for this largely untreatable disease.
Candidate outcome markers
International consensus standards for describing, analysing, and reporting many of the lesion types described herein have been published recently 3 and should facilitate cross-study comparisons and enhance generalisability of fi ndings.
Haemorrhagic markers
Symptomatic intracerebral haemorrhage is an appealing outcome for clinical trials because of its relation to the severity and pathophysiology of the underlying cerebral amyloid angiopathy, 4 apparent ease of detection, and clinical prominence. However, intracerebral haemorrhage is rare. 5 It is somewhat more common in selected groups, such as individuals with several microbleeds, 6, 7 and is most common as a recurrent event in survivors of lobar intracerebral haemorrhage, with incidence estimates ranging from 2·5% to 14·3% per year. 8 Although detection of macroscopic intracerebral haemorrhage by CT scan is technically straightforward, the presentation of intracerebral haemorrhage is sometimes too mild or non-specifi c to trigger a timely CT scan, or alternatively is, in some cases, rapidly fatal, thus precluding brain imaging.
These caveats notwithstanding, symptomatic intracerebral haemorrhage remains a reliable and clinically meaningful trial outcome in view of the high burden of Review disability associated with lobar intracerebral haemorrhage. 9 Its major limitation is effi ciency, because even recurrent lobar intracerebral haemorrhage occurs infrequently enough to need large sample sizes and long durations of follow-up. Under the optimistic assumptions that a treatment would reduce annual recurrence from 10% to 5% (ie, relative risk reduction of 50%), a randomised controlled trial with 1 year of follow-up would need an estimated 862 patients with cerebral amyloid angiopathy with previous intracerebral haemorrhage to achieve 80% statistical power, and 1154 patients for 90% power. A more conservative scenario in which annual recurrence is reduced from 10% to 8% would need 6420 patients to achieve 80% power. Restricting this calculation to patients with cerebral amyloid angiopathy deemed at high risk for intracerebral haemorrhage recurrence because of microbleed counts 10 or APOE genotype 11 would reduce the sample size needed, but would also reduce the number of available study patients. These sample size estimates suggest that intracerebral haemorrhage would be most suitable for late-phase, rather than early-phase, trials.
Cerebral microbleeds 12 are an alternative haemorrhagic marker of cerebral amyloid angiopathy. Their primary advantage as an outcome marker relative to symptomatic intracerebral haemorrhage is their substantially higher prevalence and incidence. Strictly lobar cerebral microbleeds seem to be indicative of vasculopathy related to cerebral amyloid angiopathy, but also frequently occur among presumably healthy people, possibly as a result of clinically silent cerebral amyloid angiopathy. 13, 14 Appearance of new lobar cerebral microbleeds (fi gure 1A) was reported in 6·1% of 831 elderly individuals in the general population who were rescanned a mean of 3·4 years after baseline MRI, 14 in 17·5% of the subset with one or more strictly lobar microbleeds at baseline, 14 and in 50% of 34 patients with probable cerebral amyloid angiopathy-intracerebral haemorrhage (median of three new microbleeds in patients with at least one incident lesion) rescanned after a mean of 15·8 months. 10 Although more data are needed to estimate sample sizes accurately, the greater incidence of new cerebral microbleeds compared with symptomatic intracerebral haemorrhage (in terms of both the proportion of patients aff ected and the numerical count of incident lesions) off ers substantially increased effi ciency in showing any given relative reduction in incident events.
The major drawbacks of cerebral microbleeds as a study outcome are their limited relevance as a clinically meaningful outcome, their imperfect specifi city for cerebral amyloid angiopathy, and technical issues in their detection. These lesions have less eff ect on neurological function than symptomatic intracerebral haemorrhage, although the presence of fi ve or more strictly lobar cerebral microbleeds in the general elderly population 16 or any strictly lobar cerebral microbleeds in patients with ischaemic stroke 17 have been independently linked to detectable cognitive dysfunction. Cerebral microbleeds also have clinical value as markers of increased risk of future symptomatic intracerebral haemorrhage. 10, 18 Although cerebral microbleeds are not specifi c for cerebral amyloid angiopathy, 19 the pattern of lesions restricted to lobar brain regions seems to be associated with genetic risk factors for sporadic 13, 14, 20 or familial 21 cerebral amyloid angiopathy, suggesting that this distribution might be suffi ciently specifi c to be used as an outcome measure. Finally, variations in detection of cerebral microbleeds across diff erent MRI sequence parameters, 22 fi eld strengths, 23 and raters [24] [25] [26] show the need for standardised methods in applying this marker across centres, as is done in the ongoing multicentre Restart or Stop Antithrombotics Randomised Trial (RESTART) and the Clinical Relevance Of Microbleeds In Stroke 2 (CROMIS-2) study. Microbleeds thus seem best suited to serve as an early-phase marker of treatments aimed at reducing haemorrhagic events related to cerebral amyloid angiopathy, but careful methods are needed for standardised detection and interpretation.
Recent data have implicated acute or chronic haemorrhage within or adjacent to the cortical sulci (often described as superfi cial siderosis when chronic or as convexity subarachnoid haemorrhage when acute) as another form of bleeding associated with cerebral amyloid angiopathy. Superfi cial siderosis is common in cerebral amyloid angiopathy (23 of 38 neuropathologically examined brains vs 0 of 22 brains with intracerebral haemorrhage not related to cerebral amyloid angiopathy) 27 and is often distant from sites of lobar haemorrhage, [27] [28] [29] suggesting that it is a separate bleeding event related to cerebral amyloid angiopathy. Siderosis seems to also have clinical meaning in cerebral amyloid angiopathy as a trigger of transient focal neurological symptoms 28 and a possible marker of increased risk for future intracerebral haemorrhage. 30, 31 Progression of superfi cial siderosis (fi gure 1B) presumably represents a new bleeding event and thus is a candidate cerebral amyloid angiopathy marker, but has not yet been systematically studied or measured by standardised methods.
Non-haemorrhagic markers
White matter hyperintensities of presumed vascular origin, visualised on T2-weighted or fl uid-attenuated inversion recovery (FLAIR) MRI sequences, are a ubiquitous phenomenon of ageing, but occur with much greater volume in individuals diagnosed with cerebral amyloid angiopathy than in those with healthy ageing, Alzheimer's disease, or mild cognitive impairment. 32 Although the precise pathophysiology of white matter hyperintensities remains ill defi ned (and probably heterogeneous), a vascular basis is suggested by the association with cerebral small-vessel diseases such as cerebral amyloid angiopathy and with vascular risk factors. The volume of white matter hyperintensities can be Review assessed visually by ordinal rating scales or by volumetric methods, which are usually semi-automated. Progression of white matter hyperintensities between scans (fi gure 1C) can be measured by qualitative scales 33 or quantitative methods. 34 Findings from a study 35 in 26 patients (mean age 69·1 years) with probable or possible cerebral amyloid angiopathy scanned 1-2 years apart showed a median growth in white matter hyperintensities of 0·5 mL per year (IQR 0·1-2·8 mL per year). This pace of progression is rapid relative to population-based estimates in people with healthy ageing 36 and similar to that in the subset of individuals with early confl uent or confl uent white matter hyperintensities at baseline in the population-based Austrian Stroke Prevention Study. 37 The association between white matter hyperintensities and cognitive impairment before stroke in cerebral amyloid angiopathy, 38 and the presence of cognitive impairment, disability, and future decline in other groups of patients, [39] [40] [41] [42] [43] suggest that assessment of white matter hyperintensities could be a means to measure a clinically meaningful aspect of small-vessel-related brain injury. However, large follow-up studies in cerebral amyloid The feasibility of measuring progression of white matter hyperintensities in multicentre studies has been shown by the incorporation of this measurement in various randomised controlled trials. [44] [45] [46] [47] [48] The reliability of volumetric methods for measurement of progression of white matter hyperintensities seems to be high, 49 but whether reliability is aff ected by inter-site variables, such as scanner manufacturer, fi eld strength, sequence type (eg, T2-weighted vs FLAIR), or scan resolution, is largely unknown. The variability introduced by these factors might be mitigated by harmonisation of scanning parameters (particularly voxel size) across sites, use of the same scanner or sequence at baseline and follow-up, and a within-participant analysis design. Because nearly all patients with cerebral amyloid angiopathy seem to show at least some growth of white matter hyperintensities over 1-2 years, 35 white matter hyperintensities probably have equal or greater ability than cerebral microbleed count to detect treatment eff ects. Data from the only published study 35 on progression of white matter hyperintensities in cerebral amyloid angiopathy suggest that 238 patients (119 per group) would be needed to detect a 50% reduction in progression of white matter hyperintensities with 80% power, or fewer patients if trials were restricted to those with the most extensive baseline white matter hyperintensities. Thus, progression of white matter hyperintensities seems to represent another promising outcome marker for early-phase trials and is a reasonably well-validated marker for cognitive disability. Its major limitations are absence of specifi city for cerebral amyloid angiopathy, the loose association between white matter hyperintensities and haemorrhagic manifestations of cerebral amyloid angiopathy (raising the possibility that drugs that block progression of white matter hyperintensities might not also block bleeding), and the cost and labour needed for serial MRI scans and volumetric measurements.
Microinfarcts, defi ned as areas of infarction only visible on histopathological examination (ie, up to about 1-2 mm) 50 have long been associated with advanced cerebral amyloid angiopathy. 51, 52 Although individually small, accumulating evidence suggests that these lesions might collectively have important independent eff ects on cognition. 50, 53 Substantial eff orts have focused on visualising microinfarcts in vivo-a prerequisite to regarding these lesions as potential outcome markers. Two emerging candidate approaches are detection of clinically silent foci of restricted diff usion by diff usionweighted imaging (DWI) [54] [55] [56] [57] and structural imaging of the mature lesions with ultra-high-fi eld MRI. 15 DWI lesions (fi gure 1D), typically several millimetres in diameter on MRI, are postulated (but without neuropathological confi rmation) to represent acute microinfarcts at the large end of the microinfarct size spectrum. Such lesions have been reported in about 10-20% of patients with cerebral amyloid angiopathy imaged either at the time of intracerebral haemorrhage or in the chronic postintracerebral haemorrhage period, [54] [55] [56] [57] suggesting that they might represent a marker of ongoing brain injury related to cerebral amyloid angiopathy. Recently, structural imaging at 7 T has revealed small FLAIR hyperintense and T1 hypointense lesions (fi gure 1E), with MRI-histopathological correlation at post mortem, confi rming this appearance as bona-fi de microinfarcts. 15 A key limitation of both approaches is their ability to detect lesions only at the upper limit of microinfarct size, leaving most microinfarcts (with an estimated mean diameter of about 0·3 mm) 58 undetectable with present neuroimaging. Other remaining challenges are the still undefi ned association between DWI and 7 T FLAIR lesions, the temporal limitations of DWI (hyperintensities are typically visible only 1-2 weeks after infarction), and the generalisability of these methods across centres. The clinical eff ect of microinfarcts on cognitive function and future haemorrhagic or ischaemic stroke risk in patients with cerebral amyloid angiopathy also remains to be identifi ed. Data suggest that both the overall lesion burden 58 and incidence of new lesions 54, 55 are greater for microinfarcts than for cerebral microbleeds, thus highlighting their potential for high statistical effi ciency as an outcome if they could be sensitively detected.
Diff usion tensor imaging (DTI) obtained from multidirectional MRI diff usion gradients allows measurement of the amount (mean diff usivity) and directional bias (fractional anisotropy [FA]) of water diff usion throughout the brain. In a study of 11 participants with intracerebral haemorrhage related to cerebral amyloid angiopathy and 13 matched healthy control individuals, reduced FA was found in the temporal white matter (inferior longitudinal and occipital fasciculi, 17% reduction) and splenium of the corpus callosum (15% reduction) and increased FA of lower magnitude was found in deep grey matter structures. 59 The changes were bilateral and did not seem to be aff ected by the hemisphere in which the cerebral haemorrhage was located. In another study of global mean diff usivity in 49 patients with cerebral amyloid angiopathy, higher values were seen among patients with pre-intracerebral haemorrhage cognitive impairment than among those without. 60 These data suggest that the white matter microstructure is abnormal in cerebral amyloid angiopathy and can be measured with DTI. However, further validation is needed, in particular to identify whether clinically relevant changes can be detected over time, as has been suggested for other smallvessel diseases. 61 Standardised DTI seems to be feasible across scanners and sites. 62 Other techniques developed to probe the microstructure of cerebral white matter, such as magnetisation transfer imaging, MR spectroscopy, and quantitative mapping of magnetic resonance parameters (eg, proton density, T1, T2, and T2*), have yet to be applied or validated in the context of cerebral amyloid Review angiopathy, but hold promise on the basis of reports on ageing and ischaemic small-vessel disease. 63 Enlarged perivascular spaces (also termed VirchowRobin spaces), the potential spaces surrounding small parenchymal blood vessels, represent another candidate non-haemorrhagic marker visible on MRI. Enlarged or dilated perivascular spaces, presumed to be due to the accumulation of interstitial fl uid, have been linked to the presence and severity of cerebral small-vessel disease. 64, 65 Cerebral amyloid angiopathy seems to be preferentially associated with high numbers of visible perivascular spaces in the centrum semiovale, 66, 67 which is consistent with the known localisation of cerebral amyloid angiopathy to the superfi cial cortical vessels. Enlarged perivascular spaces will need analysis for incident appearance over time, standardisation across sites, and correlation with clinical status if they are to be assessed as a potential outcome marker.
Cognitive function markers
Along with symptomatic intracerebral haemorrhage, cognitive decline is the most clinically salient manifestation of cerebral amyloid angiopathy. Findings from several studies have shown the association of cerebral amyloid angiopathy with cognitive impairment across cohorts, institutions, and countries. [68] [69] [70] [71] [72] [73] [74] In the Religious Orders Study, 74 individuals with moderate-tovery-severe cerebral amyloid angiopathy pathological abnormalities at autopsy (18·9% of the 404 study participants) showed worse perceptual speed and episodic memory than those with none-to-minimum cerebral amyloid angiopathy; this diff erence was independent of Alzheimer's disease pathology, cerebral infarcts, Lewy bodies, age at death, sex, and education in a multivariable analysis. The precise mechanism by which advanced cerebral amyloid angiopathy gives rise to cognitive impairment remains undefi ned and could represent the cumulative eff ects of the various haemorrhagic and non-haemorrhagic tissue injuries discussed earlier as well as the contribution from coexistent Alzheimer's disease pathology. Vascular amyloid itself might also trigger reactive changes and neuronal degeneration in surrounding tissue. 75 Prevention of cognitive decline, like prevention of symptomatic intracerebral haemorrhage, represents a clinically meaningful outcome appropriate for late-phase trials, although it is ineffi cient for early-phase studies. One theoretical advantage of cognition as an outcome is that it might be sensitive to cumulative changes across many haemorrhagic and non-haemorrhagic lesion types, potentially showing a sum of treatment eff ects too small to be detected individually. Cognitive testing also has the advantages of using methods that are well accepted by academic and industrial organisations (although primarily developed for Alzheimer's disease rather than vascular cognitive impairment), validated across examiners and institutions, cost-eff ective, time effi cient, quantitative, and measurable longitudinally. These advantages are off set by the non-specifi city of any cognitive test battery for cerebral amyloid angiopathy and the absence so far of a sensitive and specifi c cognitive profi le to discriminate cerebral amyloid angiopathy from other age-related disorders, because episodic memory and perceptual speed 74 overlap with domains aff ected in Alzheimer's disease and other common dementias. Moreover, the absence of a clear link between cognitive functioning and any injury type related to cerebral amyloid angiopathy also limits the ability of these measures to provide specifi c pathophysiological information on the biological eff ects of candidate treatments. Finally, cognitive impairment related to cerebral amyloid angiopathy probably represents brain injury that is largely irreversible and thus trials of suffi cient size and duration are needed for substantial progression to occur in untreated participants. No information is yet available on the rate of cognitive decline in cerebral amyloid angiopathy.
Markers of vascular pathophysiology
The haemorrhagic and non-haemorrhagic structural lesions and cognitive measures discussed seem to represent vascular-mediated injury to the brain rather than abnormalities of the vessels themselves. Thus, they probably measure late and irreversible steps in the postulated pathways leading from vascular dysfunction to brain injury and clinical dysfunction. An eff ective treatment might prevent future changes in these markers, but studies to detect this eff ect need to be large and long enough for suffi cient new injuries to occur in the untreated participants. Conversely, direct markers of pathological and physiological vessel abnormalities might not only be blocked from worsening, but might also be improved by an eff ective treatment. A marker that is reversible might provide the highest level of statistical effi ciency, allowing the possibility of smaller and shorter studies of candidate therapies.
Vascular amyloid can be detected and quantifi ed by PET scanning with the amyloid radioligand C 11 -labelled Pittsburgh Compound B (PiB). Although this compound was initially developed to detect β-amyloid deposits in Alzheimer's disease, several studies have shown increases in both global and occipital lobe PiB retention in patients with non-demented sporadic 76, 77 and familial 78 cerebral amyloid angiopathy and at foci of past 79 and future 80 haemorrhagic lesions related to cerebral amyloid angiopathy. Higher PiB retention is also independently associated with greater burden of white matter hyperintensities in patients with cerebral amyloid angiopathy but not in those with Alzheimer's disease or in healthy elderly participants, 32 suggesting a link with non-haemorrhagic as well as haemorrhagic brain injury related to cerebral amyloid angiopathy.
Amyloid load could potentially serve as an outcome marker for early-phase studies aimed at reversing or preventing vascular amyloid deposition. This approach Review has been used in conjunction with anti-amyloid antibody infusion to show reduction of PiB retention in patients with Alzheimer's disease 81 and clearance of cerebral amyloid angiopathy in a transgenic mouse model. 82 However, whether reduction of vascular amyloid burden in patients with cerebral amyloid angiopathy will have benefi cial clinical eff ects is unknown; such benefi ts have not yet been shown with amyloid clearance in Alzheimer's disease. 83 Among other hurdles to be overcome in applying amyloid imaging to cerebral amyloid angiopathy trials are the specialised facilities needed and the high cost of production of radiolabelled amyloid ligands, the non-specifi city of present radiolabelled ligands for vascular versus plaque amyloid, and the absence of natural history data on rate of vascular amyloid progression. Fluorine-18-labelled amyloid ligands such as ¹⁸F-fl orbetapir, 84 which have longer halflives and are therefore less expensive and logistically demanding than carbon-11 compounds, have been developed for Alzheimer's disease, although these have not yet been tested in cerebral amyloid angiopathy. Also, methods for undertaking and analysing PiB-PET across several sites have been developed by the Alzheimer's Disease Neuroimaging Initiative 85 and other multicentre collaborations.
Cerebral amyloid angiopathy is also associated with altered vascular reactivity to physiological stimulation. Findings from studies measuring the functional MRI (fMRI) blood oxygen level-dependent (BOLD) response to visual stimulation (fi gure 2) showed that patients with cerebral amyloid angiopathy had 27-28% reduced peak amplitude, 86, 87 73% longer time to peak, and 42% longer time to return to baseline 86 compared with control participants matched for age. Altered BOLD response might represent either vascular or neuronal dysfunction, but the fi ndings that patients with cerebral amyloid angiopathy and control individuals had similar visual-evoked response potentials 87 and that similar results occurred in analyses restricted to responding voxels only 86 suggest that the diff erences are due to the eff ects of cerebral amyloid angiopathy on the vessels themselves. The fMRI response to visual stimulation seems to be associated with markers of the severity of cerebral amyloid angiopathy, such as microbleed count and volume of white matter hyperintensities, 86, 87 suggesting that these para meters might mark the underlying extent of disease and represent a potentially important mechanism for its pathogenesis. Like vascular amyloid deposition, impaired vascular reactivity is at least partly reversible in transgenic mouse 86 The amplitude of the modelled peak response in this participant decreased from 1·06% at baseline to 0·80% at 1 year. BOLD=blood oxygen level dependent. 88, 89 raising the possibility that BOLD fMRI might serve as an effi cient marker for trials aimed at reducing the eff ects of amyloid on vessel physiology. However, the reproducibility of this approach across several timepoints and study sites remains to be established.
Circulating biomarkers
Biomarkers in CSF or plasma off er another approach for measurement of underlying, potentially reversible aspects of cerebral amyloid angiopathy pathogenesis. Two studies 90, 91 of CSF from patients with cerebral amyloid angiopathy found reductions in β-amyloid 40 and β-amyloid 42 , with phosphotau and total tau concentrations above those in elderly control individuals but lower than in patients with Alzheimer's disease. These fi ndings are broadly consistent with the patho logical abnormalities that occur in cerebral amyloid angiopathy, which entail vascular deposition of β-amyloid 40 and β-amyloid 42 and inconsistent coexistence of tau-containing lesions. The association between CSF β-amyloid and progression of cerebral amyloid angio pathy has yet to be explored; by analogy to Alzheimer's disease, 92 one might expect the reductions in CSF β-amyloid in cerebral amyloid angiopathy to be associated inversely with, and have the same meaning as, amyloid burden in cerebral amyloid angiopathy measured by PiB-PET.
Findings from a study of plasma β-amyloid showed raised β-amyloid 40 and β-amyloid 42 concentrations in patients with probable cerebral amyloid angiopathy compared with healthy control individuals 93 -diff erences not seen in an earlier analysis. 94 Another candidate family of molecules, the matrix metallo proteinases (MMPs) MMP-2 and MMP-9, are highly expressed near intracerebral haemorrhage related to cerebral amyloid angiopathy, but are not raised in plasma of patients with cerebral amyloid angiopathy. 95 These circulating biomarker studies are substantially limited by the small number of patients with cerebral amyloid angiopathy examined (fewer than 100 patients so far) and the absence of data on reproducibility across sites and longitudinal change with disease progression.
Conclusions and recommendations
Several lessons and plans for future studies can be drawn from this overview of outcome markers for cerebral amyloid angiopathy trials (table). Markers exist for most of the postulated steps in cerebral amyloid angiopathy pathogenesis, ranging from vascular amyloid deposition itself to physiological alterations, haemorrhagic and nonhaemorrhagic structural damage, symptomatic haemorrhagic stroke, and cognitive dysfunction. Thus, pilot trials are possible for cerebral amyloid angiopathy in which one or more of these markers is used to show a particular biological activity of a candidate therapy, such as use of PiB-PET to show partial clearance of plaques in the phase 2 study of bapineuzumab in Alzheimer's disease. 81 Such pilot trials might be particularly effi cient when using potentially reversible markers such as amyloid imaging and vascular reactivity. However, none of the imaging biomarkers has yet been linked closely enough to neurological impairment to serve as a true surrogate marker of clinically meaningful treatment eff ects. Thus, symptomatic intracerebral haemorrhage and cognitive testing remain the only reasonably valid outcomes for studies aimed at showing clinical benefi t.
Although the pathogenic mechanisms and data reviewed herein focus specifi cally on cerebral amyloid angiopathy, many of the considerations and fi ndings can be generalised to all forms of cerebral small-vessel disease associated with vascular cognitive impairment. Despite increasing understanding of the biology of these smallvessel processes, there are few established treatments for prevention of vascular cognitive impairment; control of hypertension was the only class I recommendation for patients at risk of vascular cognitive impairment in a scientifi c statement from the American Heart Association/American Stroke Association. 96 Trials to establish specifi c therapies for common age-related small-vessel pathological abnormalities, such as those for 13, 56, [97] [98] [99] suggesting that these markers might represent general features of damage to the small cerebral vessels. However, no in-vivo methods have yet emerged to measure arteriolosclerosis pathology in a similar way to PiB detection of cerebral amyloid angiopathy, highlighting the importance of achieving further progress in molecular imaging of small-vessel diseases.
Data that strengthen the links between imaging biomarkers and neurological function would allow greater reliance on these more effi cient surrogate markers of clinical outcome in future trials. Based on present data, the volume of white matter hyperintensities seems to have the closest association with cognition, and microbleeds the closest association with symptomatic intracerebral haemorrhage, but improved imaging modalities and larger study populations may provide stronger support for other neuroimaging markers or combinations of markers. Other key areas of need are identifi cation of the rates of biomarker progression over time and validation of imaging methods across sites; both are prerequisites for the ultimate goal of multicentre biomarker-based interventional trials. Further growth in the range of trial outcome markers, together with improved mechanistic understanding of small-vessel degeneration, will provide a strong foundation for identifying successful disease-modifying treatments for cerebral amyloid angiopathy and related diseases.
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